Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy

NCT04829708 | Recruiting Phase 3

• 1 other identifier: LS-SCLC-III-PCI 2021
• Study Type: interventional
• Target: 534
• Locations: 1 country
• Sites: 2

Brief Summary

This is a prospective, open,multicenter, randomized controlled phase III clinical trial. In patients with LS-SCLC who achieve remission after first-line chemoradiotherapy, the efficacy and safety of PCI or MRI surveillance is evaluated and analyzed. PCI is performed in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. MRI surveillance alone (delaying radiation until the actual brain metastasis) may be not inferior to PCI.

Conditions

Limited Stage Small Cell Lung Cancer

Keywords

prophylactic cranial irradiation (PCI); MRI surveillance

Outcome Measures

Primary Outcomes (1)

• Overall survival (OS)

  To compare the efficacy of PCI and MRI surveillance in patients with LS-SCLC.

  From date of randomization until the date of death due to any cause, assessed up to 2 years.

Secondary Outcomes (5)

• 1-year overall survival rate (1y-OS%)

  1-year

• 3-year overall survival rate (3y-OS%)

  3-year

• Progression-free survival (PFS)

  From the date of randomization until the date of the first onset of disease progression or the time to die of any cause, whichever occurs first, assessed up to 2 years.

• Brain metastasis rate

  From the date of randomization until the date of occurrence of brain metastasis, assessed up to 2 years.

• Cumulative incidence of neurocognitive impairment

  From the date of randomization until the date of occurrence of neurocognitive impairment , assessed up to 2 years.

Study Arms (2)

PCI Arm

ACTIVE COMPARATOR

Patients received PCI (recommended hippocampal protection) within 6 weeks after first-line treatment, with a total dose of 25 Gy, 2.5 Gy each time, once a day, 5 times a week, a total of 10 times. Brain enhancement MRI examination is performed every 3 months in first two years, and then performed every 6 months until the brain metastasis occur.

Other: MRI Surveillance; Radiation: Prophylactic Cranial Irradiation

MRI Arm

EXPERIMENTAL

Patients undergo enhancement MRI examination every 3 months in first two years, and then performed every 6 months until the brain metastasis occur. Once brain metastases occur, brain radiotherapy and systemic treatment should be conducted with the follow-up observation of brain enhancement MRI continuing.

Other: MRI Surveillance

Interventions

MRI Surveillance OTHER

Receive MRI surveillance

Also known as: Magnetic Resonance Imaging

MRI Arm; PCI Arm

Prophylactic Cranial Irradiation RADIATION

Receive PCI

Also known as: PCI

PCI Arm

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histological or cytological confirmation of LS-SCLC before first-line chemoradiotherapy (according to the staging system of the Veterans' Affairs Lung Study Group (VALSG), Appendix 2)；
• Remission is achieved after first-line chemoradiotherapy (CR or PR determined by RECIST v1.1)；
• Brain MRI examination should be performed to exclude metastatic lesions of brain parenchyma and meninges within four weeks before enrollment；
• The ECOG PS score was 0\~2；
• The interval between the end of the last treatment cycle and the randomized grouping should be no more than 8 weeks；
• Estimated survival time ≥ 12 weeks；
• Patients must agree to participate in the study, comply with the research plan and follow-up process. Written informed consent must obtained.
• Male or female aged≥18 and≤75 years old;
• For fertile women and man: Subjects are required to agree to maintain abstinence (no heterosexual intercourse) or use contraception with an annual failure rate of less than 1% during the study treatment period and within at least 6 months after the end of the study treatment period.
• Hematological indexes: absolute neutrophil count≥1.5×109/ L, platelet count≥75×109 /L, haemoglobin≥9.0g/dL, serum albumin≥3g/dL；
• Liver function: serum total bilirubin level≤1.5 times normal upper limit (ULN), glutamic pyruvic transaminase, glutamic oxaloacetic transaminase and alkaline phosphatase≤2.5 times ULN；
• Renal function: defined as serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance ≥ 15ml/min (Cockcroft-Gault formula, Appendix 4); urinary protein negative or less than 2g in routine urine examination, or 24-hour urinary protein \< 1g；
• Good clotting function, defined as international standardized ratio (INR) or prothrombin time (PT) ≤ 1.5x ULN;. If the subject is receiving anticoagulant therapy, as long as PT is within the range of anticoagulant use；
• Women of childbearing age must undergo a urinary pregnancy test within 7 days before the start of treatment and the results are negative and are not breastfeeding.

You may not qualify if:

• Patients with extensive SCLC (Appendix 2)；
• The subjects are confirmed to have brain or meningeal metastasis before they are randomly divided into groups；
• During the 5 years before the start of the study, patients with malignant tumors other than SCLC, diseases with negligible risk of metastasis or death (such as expected 5-year OS \> 90%) and malignant tumors expected to be cured (such as fully treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated by curable surgery, ductal carcinoma in situ treated by curable surgery)；
• Previous head and neck radiation fields overlapped with PCI field；
• MRI examination contraindicated
• There is evidence that significantly uncontrolled concomitant disease may affect the compliance of the study program, including severe liver disease (such as liver cirrhosis), uncontrollable major seizures or superior vena cava syndrome；
• Major cardiovascular diseases, myocardial infarction or cerebrovascular events within 3 months before randomization, unstable arrhythmias, or unstable angina pectoris；
• Patients with known coronary artery disease, congestive heart failure that do not meet the above criteria, or left ventricular ejection fraction ((LVEF)) \< 50% must receive a stable treatment plan and optimize it according to the advice of the attending physician, and consult a cardiologist if necessary。
• Stroke (including hemorrhagic and ischemic) or transient ischemic attack occurred within 6 months before enrollment；
• There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before entering the group, such as gastrointestinal bleeding, gastric ulcer bleeding, active hemoptysis or vasculitis；
• Serious arteriovenous thrombosis events occurred within 3 months before enrollment, such as deep venous thrombosis, pulmonary embolism, etc. (except for implantable venous infusion port, catheter-derived thrombosis or superficial venous thrombosis, these conditions are not considered "severe" thromboembolism);
• Diabetic ketoacidosis or hyperglycemia and hyperosmosis occurred in the past 6 months;
• There was a history of hypertensive crisis and hypertensive encephalopathy;
• Any other disease, metabolic disorder, abnormal result of physical examination or laboratory examination, and there is reason to suspect that it may affect the reliability of the results of the study or put the patient at high risk of treatment complications；
• The results of HIV test is positive

Sponsors & Collaborators

• Shandong Cancer Hospital and Institute: lead

Study Sites (2)

Shandong Cancer Hospital and Institute

Jinan, Shandong, 250117, China

RECRUITING

Shandong Cancer Hospital

Jinan, China

RECRUITING

MeSH Terms

Interventions

Magnetic Resonance Spectroscopy

Intervention Hierarchy (Ancestors)

Spectrum Analysis; Chemistry Techniques, Analytical; Investigative Techniques

Study Officials

• Jinming Yu, PhD

  Shandong Cancer Hospital and Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jinming Yu, PhD

CONTACT

+8613806406293; sdyujinming@126.com

Xiangjiao Meng, PhD

CONTACT

+8613793150996; mengxiangjiao@126.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Shandong Cancer Hospital and Institute

Study Record Dates

• First Submitted: March 27, 2021
• First Posted: April 2, 2021
• Study Start: April 26, 2021
• Primary Completion: April 15, 2026
• Study Completion (Estimated): April 15, 2028
• Last Updated: April 29, 2021

Record last verified: 2021-04

Locations

CN (2)